

DAFTAR PUSTAKA

1. WHO. cancer [Internet]. 2022 [cited 2022 Feb 7]. Available from: <https://www.who.int/news-room/fact-sheets/detail/cancer>
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021;71(3):209–49.
3. (OMS) WHO. Estimated number of new cases in 2020, Asia, both sexes, all ages. *Glob Cancer Obs* [Internet]. 2020;428:2020. Available from: <https://gco.iarc.fr/today/online-analysis-pie>
4. Penyakit Kanker di Indonesia Berada Pada Urutan 8 di Asia Tenggara dan Urutan 23 di Asia – P2P Kemenkes RI [Internet]. [cited 2022 Feb 9]. Available from: <http://p2p.kemkes.go.id/penyakit-kanker-di-indonesia-berada-pada-urutan-8-di-asia-tenggara-dan-urutan-23-di-asia/>
5. Indra. Sosialisasi Hari Kanker Sedunia (World Cancer Day) Dengan Guru SMA 1 Padang [Internet]. [cited 2022 Feb 9]. Available from: <https://dinkes.sumbarprov.go.id/details/news/467>
6. Megawati. Gambaran Ketahanan Hidup Lima Tahun Pasien Kanker Payudara Berdasarkan Karakteristik Demografi dan Faktor Klinis di Rumah Sakit Cipto Mangunkusumo Tahun 2007-2010. *eSkripsi Univ Indones.* 2012;5–20.
7. Aswar MKS. Hubungan Antara Rasio Neutrofil Limfosit dan Stadium Klinis pada Pasien Kanker Payudara di RSUP DR Wahidin Sudirohusodo Periode Januari - Desember 2018. *eSkripsi Univ Hasanuddin.* 2019;56.
8. Forget P, Khalifa C, Defour JP, Latinne D, Van Pel MC, De Kock M. What is the normal value of the neutrophil-to-lymphocyte ratio? Vol. 10, *BMC Research Notes.* 2017. p. 1–4.
9. Rosales C. Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types? *Front Physiol* [Internet]. 2018 Feb 20 [cited 2022 Feb 14];9. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826082/>
10. Listy BL. Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill [Internet]. [cited 2022 Feb 23]. Available from: <https://pubmed.ncbi.nlm.nih.gov/11723675/>
11. Faria SS, Fernandes PC, Silva MJB, Lima VC, Fontes W, Freitas R, et al. The neutrophil-to-lymphocyte ratio: a narrative review. *Ecancermedicalscience* [Internet]. 2016 Dec 12 [cited 2022 Feb 23];10. Available from:

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221645/>

12. Clara I. Hubungan Antara Jumlah Neutrofil dan Limfosit pada Kanker Payudara. eSkripsi Univ Sumatera Utara. 2019;1–71.
13. Panigroro S, Hernowo BS, Purwanto H. Panduan Penatalaksanaan Kanker Payudara (Breast Cancer Treatment Guideline). J Kesehat Masy [Internet]. 2019;4(4):1–50. Available from: <http://kanker.kemkes.go.id/guidelines/PPKPayudara.pdf>
14. Stanisławek A. Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies— An Updated Review. 2021;1–30.
15. Gordon BL. A Textbook of Histology. Vol. 175, Jama. 1961. 637 p.
16. Yi-Sheng Sun¹, Zhao Zhao², Zhang-Nv Yang¹, Fang Xu¹, Hang-Jing Lu¹, Zhi-Yong Zhu¹, Wen Shi¹, Jianmin Jiang¹, Ping-Ping Yao¹ □ H-PZ. Risk Factor and Preventions of Breast Cancer. IVYSPRING Int Publ. 2017;13:1–11.
17. Zhang Z, Zeng P, Gao W, Zhou Q, Feng T, Tian X. Circadian clock: a regulator of the immunity in cancer. Cell Commun Signal. 2021 Dec 1;19(1).
18. Suardana IBK. Imunologi Dasar Sistem Imun. [Http://SimdosUnudAcId](http://SimdosUnudAcId) [Internet]. 2017;1–36. Available from: https://simdos.unud.ac.id/uploads/file_pondidikan_1_dir/284a0e69155751dc6c459b07f14bc03c.pdf
19. Kemenkes RI. Pedoman Interpretasi Data Klinik. Kementrian Kesehat RI. 2011;(January):1–83.
20. Mohamed MM, Mahgoub NM, Osman NM, Saeed SS, Elmubark TY, Abass A-E. Reference Value of Neutrophil-Lymphocyte Ratio in Healthy Sudanese in Khartoum. Sch J Appl Med Sci [Internet]. 2017 [cited 2022 May 30];5(5C):1915–9. Available from: <http://saspublisher.com/sjams/>
21. Nah E-H, Kim S, Cho S, Cho H-I. Complete Blood Count Reference Intervals and Patterns of Changes Across Pediatric, Adult, and Geriatric Ages in Korea. Ann Lab Med. 2018;38.
22. Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, et al. Usefulness of the Neutrophil-to-Lymphocyte Ratio in Predicting Short- and Long-Term Mortality in Breast Cancer Patients. Ann Surg Oncol. 2012;19(1):217–24.
23. Noh H, Eomm M, Han A. Usefulness of Pretreatment Neutrophil to Lymphocyte Ratio in Predicting Disease-Specific Survival in Breast Cancer Patients. J Breast Cancer. 2013;16(1):55–9.

24. Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G. Breast cancer. *Lancet*. 2005 May 14;365(9472):1727–41.
25. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. *Ann Oncol*. 2019;30(8).
26. Sander MA. Profil Penderita Kanker Payudara Stadium Lanjut Baik Lokal Maupun Metastasis Jauh Di Rsup Hasan Sadikin Bandung. *Farmasains J Farm dan Ilmu Kesehat*. 2012;1(2).
27. Hassan LM, Mahmoud N, Miller AB, Iraj H, Mohsen M, Majid J, et al. Evaluation of Effect of Self-Examination and Physical Examination on Breast Cancer. *Breast*. 2015;24(4):487–90.
28. Fiorica J V. Breast Cancer Screening, Mammography, and Other Modalities. *Clin Obstet Gynecol*. 2016 Dec 1;59(4):688–709.
29. Shah R, Rosso K, David Nathanson S. Pathogenesis, Prevention, Diagnosis and Treatment of Breast Cancer. *World J Clin Oncol*. 2014 Aug 10;5(3):283–98.
30. Shah T, Guraya S. Breast Cancer Screening Programs: Review of Merits, Demerits, and Recent Recommendations Practiced Across The World. *J Microsc Ultrastruct* [Internet]. 2016;59. Available from: <http://dx.doi.org/10.1016/j.jmau.2016.10.002>
31. Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, et al. Surveillance of BRCA1 and BRCA2 Mutation Carriers With Magnetic Resonance Imaging, Ultrasound, Mammography, and Clinical Breast Examination [Internet]. Vol. 292, *JAMA*. 2004. Available from: www.jama.com
32. Giuliano AE, Edge SB, Hortobagyi GN. Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer. *Ann Surg Oncol* [Internet]. 2018;25(7):1783–5. Available from: <https://doi.org/10.1245/s10434-018-6486-6>
33. Breast Cancer Stages [Internet]. American Cancer Society. [cited 2022 May 27]. Available from: <https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/stages-of-breast-cancer.html>
34. Smoot B, Wampler M, Topp KS. Breast Cancer Treatments and Complications: Implications for Rehabilitation. *Rehabil Oncol*. 2009;27(3):16–26.
35. Survival statistics for breast cancer | Canadian Cancer Society [Internet]. Canadian Cancer Society. [cited 2022 May 27]. Available from: <https://cancer.ca/en/cancer-information/cancer-types/breast/prognosis-and->

survival/survival-statistics

36. Gray JM, Rasanayagam S, Engel C, Rizzo J. State of the evidence 2017: An update on the connection between breast cancer and the environment. *Environ Heal A Glob Access Sci Source*. 2017;16(1):1–61.
37. Helyer LK, Varnic M, Le LW, Leong W, McCreedy D. Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients. *Breast J*. 2010;16(1):48–54.
38. Pashayan N, Antoniou AC, Ivanus U, Esserman LJ, Easton DF, French D, et al. Personalized early detection and prevention of breast cancer: ENVISION consensus statement. *Nat Rev Clin Oncol* [Internet]. 2020;17(11):687–705. Available from: <http://dx.doi.org/10.1038/s41571-020-0388-9>
39. Bazzi T, Al-husseini M, Saravolatz L, Kafri Z. Trends in Breast Cancer Incidence and Mortality in the United States From 2004-2018 : A Surveillance , Epidemiology , and End Results (SEER) -Based Study Baseline characteristics. 2023;2023(Cdc):4–9.
40. Rahayu SA, Arania R. Hubungan Usia dan Paritas Dengan Kejadian Kanker Payudara di RSUD Dr.H.Abdul Moeloek Bandar Lampung Tahun 2017 [Internet]. Vol. 5, *Jurnal Ilmu Kedokteran dan Kesehatan*. 2018. p. 44. Available from: <http://www.ejurnalmalahayati.ac.id/index.php/kesehatan/article/view/786>
41. Milosevic M, Jankovic D, Milenkovic A, Stojanov D. Early diagnosis and detection of breast cancer. *Technol Heal Care*. 2018;26(4):729–59.
42. Abdulrahman GO, Rahman GA. Epidemiology of breast cancer in Europe and Africa. *J Cancer Epidemiol*. 2012;2012:1–6.
43. Rondonuwu IA, Haroen H, Wantania F. Profil Kanker Payudara Rsup Prof. Dr. R. D. Kandou Manado Tahun 2013 – 2014. *e-CliniC (eCL)*. 2016;4(1).
44. Nurul Amalina Khairuddin. Karakteristik Sosiodemografi dan Klinis Penderita Kanker Payudara Di RSUP Wahidin Sudirohusodo dan RSP Universitas Hasanuddin Tahun 2019-2021. 2021;(March):1–19. Available from: http://repository.unhas.ac.id/id/eprint/12930/1/C011181509_skripsi_13-12-2021.pdf
45. Hisham AN, Yip C, Surgery E, Hospital P. Overview of Breast Cancer in Malaysian Women : *Asian J Surg* [Internet]. 2004;27(2):130–3. Available from: [http://dx.doi.org/10.1016/S1015-9584\(09\)60326-2](http://dx.doi.org/10.1016/S1015-9584(09)60326-2)
46. Limin X, Clegg, Marsha E. Reichman, Barry A. Miller, Benjamin F. hankey, Gopal K. Singh, Yi Dan Lin, Marc T. Goodman, Charles F. Lynch, Stephen M. Schwartz, Vivian W. Chen, Leslie Bernstein, Scarlett L. Gomez, Kohn J.

- Graff, Charles C. Lin, Norman . Johns BKE. Impact of socioeconomic status on cancer incidence and stage at diagnosis : selected findings from the surveillance , epidemiology , and end results : National Longitudinal Mortality Study. *Cancer Causes Control*. 2009;417–35.
47. Liu W, You J. Merkel Cell Polyomavirus and Human Merkel Cell Carcinoma. *Recent Results Cancer Res*. 2021;217:303–23.
 48. Jaiswal K, Hull M, Furniss AL, Doyle R, Gayou N, Bayliss E. Delays in Diagnosis and Treatment of Breast Cancer: A Safety-Net Population Profile. *JNCCN J Natl Compr Cancer Netw*. 2018;16(12):1451–7.
 49. Bhikoo R, Srinivasa S, Yu T, Moss D, Hill AG. Systematic Review of Breast Cancer Biology in Developing Countries (Part 2): Asian Subcontinent and South East Asia. 2011;2382–401.
 50. Parkin DM. Use of Statistics to Assess the Global Burden of Breast Cancer. *Breast J*. 2006;12:70–80.
 51. Widhyasih RM, Rahmadhanti SD, Fajrunni'mah R. Carcinoembryonic Antigen (CEA) dan Neutrofil-to-Limfosit Ratio (NLR) sebagai Faktor Prediktif Kanker Kolorektal. *J Ilmu dan Teknol Kesehat*. 2019;7(1):68–76.
 52. Wu L, Saxena S, Awaji M, Singh RK. Tumor-associated neutrophils in cancer: Going pro. *Cancers (Basel)*. 2019;11(4).
 53. Krupicka J, Sarec P, Novak P. Immune surveillance of tumors. *Eng Rural Dev*. 2016;2016-Janua(5):1206–11.
 54. Prasetyo YE, Bahrin U, Pakasi RD. Angka Banding Neutrofil/Limfosit Di Karsinoma Payudara. *Indones J Clin Pathol Med Lab*. 2018;21(2):125–9.
 55. Irma Ningsih Yuvita Fallo. A. Sidharta LSG. Korelasi antara Neutrophyl Lymphocyte Ratio dengan Stadium Kanker pada Pasien Kanker Payudara. *Biomedikai*. 2018;1–7.
 56. Guthrie GJK, Charles KA, Roxburgh CSD, Horgan PG, Mcmillan DC, Clarke SJ. The systemic inflammation-based neutrophil – lymphocyte ratio : Experience in patients with cancer. *Crit Rev Oncol / Hematol [Internet]*. 2013;88(1):218–30. Available from: <http://dx.doi.org/10.1016/j.critrevonc.2013.03.010>
 57. Xing C. The neutrophil lymphocyte ratio is associated with breast cancer prognosis : an updated systematic review and meta-analysis. 2016;5567–75.
 58. Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-taylor AJ. Neutrophil to lymphocyte ratio and cancer prognosis : an umbrella review of systematic reviews and meta-analyses of observational studies. *BMC Med*.

2020;1–16.

59. Ethier J, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to- lymphocyte ratio in breast cancer : a systematic review and meta-analysis. *Breast Cancer Res* [Internet]. 2017;1–13. Available from: <http://dx.doi.org/10.1186/s13058-016-0794-1>
60. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil / lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. *Br J Cancer* [Internet]. 2011;104(8):1288–95. Available from: <http://dx.doi.org/10.1038/bjc.2011.100>

